tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
erlotinib "sandoz" 100 mg filmovertrukne tabletter
sandoz a/s - erlotinibhydrochlorid - filmovertrukne tabletter - 100 mg
erlotinib "sandoz" 150 mg filmovertrukne tabletter
sandoz a/s - erlotinibhydrochlorid - filmovertrukne tabletter - 150 mg
erlotinib "sandoz" 25 mg filmovertrukne tabletter
sandoz a/s - erlotinibhydrochlorid - filmovertrukne tabletter - 25 mg
erlotinib "stada" 100 mg filmovertrukne tabletter
stada arzneimittel ag - erlotinibhydrochlorid - filmovertrukne tabletter - 100 mg
erlotinib "stada" 150 mg filmovertrukne tabletter
stada arzneimittel ag - erlotinibhydrochlorid - filmovertrukne tabletter - 150 mg
erlotinib "teva b.v." 100 mg filmovertrukne tabletter
teva b.v. - erlotinibhydrochlorid - filmovertrukne tabletter - 100 mg
erlotinib "teva b.v." 150 mg filmovertrukne tabletter
teva b.v. - erlotinibhydrochlorid - filmovertrukne tabletter - 150 mg
erlotinib "teva b.v." 25 mg filmovertrukne tabletter
teva b.v. - erlotinibhydrochlorid - filmovertrukne tabletter - 25 mg
erlotinib "stada" 25 mg filmovertrukne tabletter
stada arzneimittel ag - erlotinibhydrochlorid - filmovertrukne tabletter - 25 mg